BioRelix Secures $3,644,085 New Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    5 Science Park 401 Winchester Avenue New Haven, CT 06511-1989
  • Company Description
    BioRelix, Inc. is a market-driven company that discovers and develops antibiotics that target pathogens resistant to currently available drugs. BioRelix’ competitive advantage resides in the use of novel patented bacterial RNA targets called RiboSwitches that were identified by the laboratory of BioRelix’ founder, Dr. Ronald Breaker at Yale University.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing.
  • M&A Terms
  • Venture Investor

Trending on Xconomy